Cytotherapy · 2025
A new sort of cells for chimeric antigen receptor T-cell therapies-isolating CD14-CD127+ T cells for chimeric antigen receptor T-cell manufacture.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luo Yan, Qie Yaqing, Gadd Martha E, Hundal Tanya, Brim Andrew D, Rosario Isas K Vazquez, Qin Hong
Аннотация
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy is an adoptive immunotherapy in which T cells are isolated from the patient and genetically modified ex vivo to express a CAR, thus enabling the CAR T-cells to target tumor cells. Currently, six Food and Drug Administration-approved CAR T-cell therapies target either CD19 for relapsed/refractory (R/R) B cell malignancies or B cell maturation antigen for R/R multiple myeloma. The success of these CAR T-cells has positioned this therapy as an important option for treating hematological malignancies and has also spurred efforts to use CAR T-cells to target solid tumors and to target nonmalignant B cell pathologies.
OBJECTIVE: The final functionality of CAR T-cells is influenced by the initial T cell subpopulations that were isolated, and naïve and memory phenotypes have been shown to yield superior final products. Our goal is to refine the T cell isolation method to enrich a naïve/memory T cell population for CAR T-cell production, while excluding cell subsets that could impair CAR T-cell product performance.
EXPERIMENTAL DESIGN: Healthy donor PBMCs were subjected to magnetic cell separation to deplete CD14+ cells, followed by a positive selection of CD127+ cells. The enriched CD14-CD127+ T cell population was characterized prior to CAR T-cell production. For comparison, we also generated CAR T-cells using CD14-CD25-CD62L+ T cells in an established method. Both CAR T-cell products were evaluated for production quality and compared in a series of activity assays.
RESULTS: A new isolation method was applied to healthy donor PBMCs to enrich a CD14-CD127+ T cell population. With this approach, B cell populations and monocytes were largely excluded from the final cell population, and extremely low percentages of CD4+FoxP3+ regulatory T cells (Tregs) were detected. The enriched CD14-CD127+ T cell population was largely comprised of naïve, stem-like central memory, and central memory T cells. A BAFF-R targeted CAR (MC10029) was transfected into both CD14-CD25-CD62L+ T cells and CD14-CD127+ T cells from the same donor. Both CAR T-cell products exhibited similar cytotoxic performance.
CONCLUSIONS: We developed a new two-step isolation method for enriching CD14-CD127+ T cells from PBMCs. This method effectively excluded unwanted B cells, yet maintained the naïve, stem-like central memory and central memory T cells that can produce functional CAR T-cells.
OBJECTIVE: The final functionality of CAR T-cells is influenced by the initial T cell subpopulations that were isolated, and naïve and memory phenotypes have been shown to yield superior final products. Our goal is to refine the T cell isolation method to enrich a naïve/memory T cell population for CAR T-cell production, while excluding cell subsets that could impair CAR T-cell product performance.
EXPERIMENTAL DESIGN: Healthy donor PBMCs were subjected to magnetic cell separation to deplete CD14+ cells, followed by a positive selection of CD127+ cells. The enriched CD14-CD127+ T cell population was characterized prior to CAR T-cell production. For comparison, we also generated CAR T-cells using CD14-CD25-CD62L+ T cells in an established method. Both CAR T-cell products were evaluated for production quality and compared in a series of activity assays.
RESULTS: A new isolation method was applied to healthy donor PBMCs to enrich a CD14-CD127+ T cell population. With this approach, B cell populations and monocytes were largely excluded from the final cell population, and extremely low percentages of CD4+FoxP3+ regulatory T cells (Tregs) were detected. The enriched CD14-CD127+ T cell population was largely comprised of naïve, stem-like central memory, and central memory T cells. A BAFF-R targeted CAR (MC10029) was transfected into both CD14-CD25-CD62L+ T cells and CD14-CD127+ T cells from the same donor. Both CAR T-cell products exhibited similar cytotoxic performance.
CONCLUSIONS: We developed a new two-step isolation method for enriching CD14-CD127+ T cells from PBMCs. This method effectively excluded unwanted B cells, yet maintained the naïve, stem-like central memory and central memory T cells that can produce functional CAR T-cells.